Entrada Therapeutics Valuation Multiples

Entrada Therapeutics Overview

About Entrada Therapeutics

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Founded

2016

HQ

Employees

183

Website

entradatx.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $25M

EBITDA: ($158M)

EV

$182M

Valuation Multiples

Multiples.vc

Start free trial

Entrada Therapeutics Financials

Entrada Therapeutics reported last 12-month revenue of $25M and negative EBITDA of ($158M).

In the same LTM period, Entrada Therapeutics generated $25M in gross profit, ($158M) in EBITDA losses, and had net loss of ($150M).

Entrada Therapeutics P&L

In the most recent fiscal year, Entrada Therapeutics reported revenue of $25M and EBITDA of ($154M).

Entrada Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX

Entrada Therapeutics Stock Performance

Entrada Therapeutics has current market cap of $457M, and enterprise value of $182M.

Entrada Therapeutics' stock price is $11.95.

Entrada Therapeutics Valuation Multiples

Entrada Therapeutics trades at 7.2x EV/Revenue multiple, and (1.2x) EV/EBITDA.

Entrada Therapeutics Financial Valuation Multiples

As of March 21, 2026, Entrada Therapeutics has market cap of $457M and EV of $182M.

Equity research analysts estimate Entrada Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Entrada Therapeutics has a P/E ratio of (3.0x).

Entrada Therapeutics Margins & Growth Rates

Entrada Therapeutics' revenue in the last 12 month grew by 3%.

Entrada Therapeutics' revenue per employee in the last FY averaged $0.1M.

Entrada Therapeutics' rule of 40 is (622%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Entrada Therapeutics' rule of X is (617%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Entrada Therapeutics Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Entrada Therapeutics M&A Activity

Entrada Therapeutics acquired XXX companies to date.

Last acquisition by Entrada Therapeutics was on XXXXXXXX, XXXXX. Entrada Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Entrada Therapeutics Investment Activity

Entrada Therapeutics invested in XXX companies to date.

Entrada Therapeutics made its latest investment on XXXXXXXX, XXXXX. Entrada Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).